
This Phase 1b study evaluated the preliminary efficacy, safety, and pharmacokinetics (PK) of isatuximab, an anti-CD38 monoclonal antibody, combined with bortezomib-lenalidomide-dexamethasone (Isa-VRd) in patients with NDMM ineligible for/with no intent for immediate ASCT. In the efficacy population (n = 71), the overall response rate was 98.6%, with 56.3% achieving a complete response or better and 50.7% patients reaching minimal residual disease negativity.
Like
Save
Share